An anti-EpCAM x CD3 BsAb is designed to address on-target off-tumor of previous anti-EpCAM products by having reduced affinity for both targets at the pH in healthy tissue and higher affinity in the more acidic pH of the TME (90). The gene discussed is EPCAM; the disease is neoplasm.